Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Intervention/Treatment

    ranibizumab ...
  • Study Participants

This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.
Study Started
Nov 30
Primary Completion
Feb 28
Study Completion
Feb 28
Results Posted
Apr 29
Last Update
Apr 29

Drug ranibizumab 0.5mg

Standard dose

  • Other names: Lucentis

Drug ranibizumab 1.0mg

High dose

  • Other names: Lucentis

intravitreal ranibizumab 0.5mg Experimental

intravitreal ranibizumab 1.0mg Experimental


Inclusion Criteria:

Ability to provide written informed consent and comply with study assessments for the full duration of the study
Age > 18 years
CRVO or BRVO diagnosis
For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
Central macular edema present on clinical examination and OCT testing with a central point thickness and/or central 1mm subfield thickness > 300 microns after at least 3 months of bevacizumab or steroid therapy.
Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
Patients must demonstrate that they are no longer improving on bevacizumab or intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)
BRVO patients treated with grid laser must show residual edema three months following latest laser treatment
Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
Participation in another ocular investigation or trial simultaneously
Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
Significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy or severe epiretinal membrane)
Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)
Evidence of central atrophy or fibrosis in the study eye
Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
History of grid/focal laser or panretinal laser in the study eye in the previous three months
History of vitreous surgery in the study eye
History of use of intravitreal, peribulbar, or retrobulbar steroids within three months of the study.
History of cataract surgery within 6 months of enrollment.
History of YAG capsulotomy within 2 months of the surgery.
Visual acuity <20/400 in the fellow eye
Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.
History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.


Intravitreal Ranibizumab 0.5mg

Intravitreal Ranibizumab 1.0mg

All Events

Event Type Organ System Event Term Intravitreal Ranibizumab 0.5mg Intravitreal Ranibizumab 1.0mg

Mean Change From Baseline BCVA

Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.

Intravitreal Ranibizumab 0.5mg

Letters (ETDRS chart) (Mean)
Standard Deviation: 10

Intravitreal Ranibizumab 1.0mg

Letters (ETDRS chart) (Mean)
Standard Deviation: 6

Mean Change From Baseline in Center Point Thickness

Outcome Measure Data Not Reported

Change in Mean Best Corrected Visual Acuity From Baseline

Outcome Measure Data Not Reported

Percentage of Patients With CFT Less Than 300um

Outcome Measure Data Not Reported

Excess Foveal Thickness

Outcome Measure Data Not Reported

Total Number of Ranibizumab Injections

Outcome Measure Data Not Reported



Age, Continuous

years (Mean)
Standard Deviation: 5.0

Region of Enrollment

Sex: Female, Male

Overall Study

Intravitreal Ranibizumab 0.5mg

Intravitreal Ranibizumab 1.0mg

Drop/Withdrawal Reasons

Intravitreal Ranibizumab 1.0mg